5 Key Takeaways
-
1
RNA therapeutics have evolved significantly, with a projected market growth to $25 billion by 2030 due to increasing clinical demand.
-
2
Current solid-phase oligonucleotide synthesis (SPOS) technology faces challenges in scalability, quality, and operational costs for RNA manufacturing.
-
3
Enzyme-enabled oligonucleotide synthesis offers a promising alternative, improving scalability and product quality while reducing hazardous solvents.
-
4
Ligases facilitate modular construction of RNA sequences, enhancing flexibility and simplifying purification workflows in RNA manufacturing.
-
5
The shift towards enzymatic methods in RNA manufacturing is gaining regulatory momentum, accelerating industry adoption and innovation.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
